Nuzyra Side Effects

Generic name: omadacycline

Medically reviewed by Drugs.com. Last updated on Feb 6, 2024.

Note: This document provides detailed information about Nuzyra Side Effects associated with omadacycline. Some dosage forms listed on this page may not apply specifically to the brand name Nuzyra.

Applies to omadacycline: oral tablet.

Other dosage forms:

• intravenous powder for solution

Common side effects of Nuzyra

Some side effects of omadacycline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• nausea
• vomiting

Less common

• belching
• change or loss in taste
• constipation
• diarrhea
• feeling of constant movement of self or surroundings
• heartburn
• increased sweating
• indigestion
• mouth or throat pain
• sensation of spinning
• stomach discomfort or upset
• trouble sleeping
• unusual drowsiness, dullness, or feeling of sluggishness

Serious side effects of Nuzyra

Along with its needed effects, omadacycline (the active ingredient contained in Nuzyra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking omadacycline:

Less common

• blurred vision
• dizziness
• fainting
• fast, pounding, or irregular heartbeat or pulse
• fever
• headache
• hives, itching, skin rash
• hoarseness
• irritation
• itching of the vagina or genitals
• joint pain, stiffness, or swelling
• nervousness
• pale skin
• pounding in the ears
• redness of the skin
• sore mouth or tongue
• stomach pain
• swelling of the eyelids, face, lips, hands, or feet
• thick, white vaginal discharge with mild or no odor
• tightness in the chest
• troubled breathing or swallowing
• troubled breathing with exertion
• unusual bleeding or bruising
• unusual tiredness or weakness
• white patches in the mouth or on the tongue

For healthcare professionals

Applies to omadacycline: intravenous powder for injection, oral tablet.

General

In the community-acquired bacterial pneumonia clinical trial, serious side effects were reported in 6% of patients treated with this drug and 6.7% of patients treated with moxifloxacin; therapy was discontinued due to any side effect in 5.5% of patients treated with this drug and 7% of patients treated with moxifloxacin. In the pooled acute bacterial skin and skin structure infection trials, serious side effects were reported in 2.3% of patients treated with this drug and 1.9% of patients treated with comparator; therapy was discontinued due to side effects in 1.7% of patients treated with this drug and 1.5% of patients treated with comparator.^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (up to 30%), vomiting (up to 17%)
• Common (1% to 10%): Diarrhea, constipation
• Frequency not reported: Abdominal pain, dyspepsia, oral candidiasis, increased lipase^[Ref]

Local

• Common (1% to 10%): Infusion site reactions (infusion site extravasation, pain, erythema, swelling, inflammation, irritation, peripheral swelling, skin induration)^[Ref]

Hepatic

• Common (1% to 10%): Increased ALT, increased AST, increased GGT
• Frequency not reported: Increased bilirubin^[Ref]

Cardiovascular

• Common (1% to 10%): Hypertension
• Frequency not reported: Tachycardia, atrial fibrillation^[Ref]

Nervous system

• Common (1% to 10%): Headache
• Frequency not reported: Dysgeusia, lethargy, vertigo^[Ref]

Psychiatric

• Common (1% to 10%): Insomnia^[Ref]

Other

• Common (1% to 10%): Death
• Frequency not reported: Fatigue, increased alkaline phosphatase, mortality imbalance^[Ref]

In the community-acquired bacterial pneumonia clinical trial, mortality imbalance was observed with 8 deaths (2%) in patients treated with this drug compared to 4 deaths (1%) in patients treated with moxifloxacin. All deaths (both treatment groups) occurred in patients older than 65 years; most patients had multiple comorbidities. Causes of death varied and included worsening and/or complications of infection and underlying conditions. The cause of the mortality imbalance has not been established.

In acute bacterial skin and skin structure infection trials, 1 death (0.1%) was reported in patients treated with this drug and 3 deaths (0.4%) were reported in patients treated with linezolid.^[Ref]

Hematologic

• Frequency not reported: Anemia, thrombocytosis^[Ref]

Hypersensitivity

• Frequency not reported: Hypersensitivity^[Ref]

Dermatologic

• Frequency not reported: Pruritus, erythema, hyperhidrosis, urticaria^[Ref]

Respiratory

• Frequency not reported: Oropharyngeal pain^[Ref]

Musculoskeletal

• Frequency not reported: Increased creatine phosphokinase^[Ref]

Genitourinary

• Frequency not reported: Vulvovaginal mycotic infection^[Ref]

Frequently asked questions

• What type of drug is Nuzyra (omadacycline)?

Further information

Nuzyra side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer